id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2022-N-1794-0012,FDA,FDA-2022-N-1794,Agency Information Collection Activities; Announcement of Office of Management and Budget Approvals,Notice,Notice of Publication,2023-05-04T04:00:00Z,2023,5,2023-05-04T04:00:00Z,,2023-05-04T13:47:14Z,2023-09401,0,0,09000064859ca728
FDA-2022-N-1794-0011,FDA,FDA-2022-N-1794,Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; General Drug Labeling Provisions and Over-the-Counter Monograph Drug User Fee Submissions,Notice,30 Day Proposed Information Collection,2022-12-13T05:00:00Z,2022,12,2022-12-13T05:00:00Z,2023-01-13T04:59:59Z,2022-12-13T16:35:12Z,2022-27016,0,0,0900006485532493
FDA-2022-N-1794-0007,FDA,FDA-2022-N-1794,Providing Over-the-Counter Monograph Submissions in Electronic Format Guidance for Industry Draft Guidance,Other,Guidance,2022-11-25T05:00:00Z,2022,11,2022-11-25T05:00:00Z,,2024-11-07T00:43:46Z,,1,0,0900006485500a9c
FDA-2022-N-1794-0005,FDA,FDA-2022-N-1794,Nonprescription Sunscreen Drug Products Format and Content of Data Submissions Guidance for Industry,Other,Guidance,2022-11-25T05:00:00Z,2022,11,2022-11-25T05:00:00Z,,2022-11-25T18:11:15Z,,0,0,0900006485500d2b
FDA-2022-N-1794-0002,FDA,FDA-2022-N-1794,"Quantitative Labeling of Sodium, Potassium, and Phosphorus for Human Over the Counter and Prescription Drug Products; Guidance for Industry Draft Guidance",Other,Guidance,2022-11-25T05:00:00Z,2022,11,2022-11-25T05:00:00Z,,2024-11-07T00:44:01Z,,1,0,0900006485500493
FDA-2022-N-1794-0008,FDA,FDA-2022-N-1794,Assessing User Fees Under the Over-the-Counter Monograph Drug User Fee Program Guidance for Industry Draft Guidance,Other,Guidance,2022-11-25T05:00:00Z,2022,11,2022-11-25T05:00:00Z,,2024-11-07T00:43:58Z,,1,0,0900006485500da3
FDA-2022-N-1794-0009,FDA,FDA-2022-N-1794,"Quantitative Labeling of Sodium, Potassium, and Phosphorus for Human Over the Counter and Prescription Drug Products Guidance for Industry; Draft Guidance",Other,Guidance,2022-11-25T05:00:00Z,2022,11,2022-11-25T05:00:00Z,,2024-11-07T00:43:46Z,,1,0,0900006485500ab5
FDA-2022-N-1794-0003,FDA,FDA-2022-N-1794,Guidance for Industry Labeling of Nonprescription Human Drug Products Marketed Without an Approved Application as Required by the Dietary Supplement and Nonprescription Drug Consumer Protection Act: Questions and Answers,Other,Guidance,2022-11-25T05:00:00Z,2022,11,2022-11-25T05:00:00Z,,2024-11-07T00:44:01Z,,1,0,0900006485500495
FDA-2022-N-1794-0006,FDA,FDA-2022-N-1794,Nonprescription Sunscreen Drug Products— Safety and Effectiveness Data Guidance for Industry,Other,Guidance,2022-11-25T05:00:00Z,2022,11,2022-11-25T05:00:00Z,,2025-02-18T02:00:37Z,,1,0,0900006485500a98
FDA-2022-N-1794-0010,FDA,FDA-2022-N-1794,Formal Meetings Between FDA and Sponsors or Requestors of Over-the-Counter Monograph Drugs Guidance for Industry Draft Guidance,Other,Guidance,2022-11-25T05:00:00Z,2022,11,2022-11-25T05:00:00Z,,2024-11-12T23:47:19Z,,1,0,0900006485500d34
FDA-2022-N-1794-0004,FDA,FDA-2022-N-1794,Statement of Identity and Strength — Content and Format of Labeling for Human Nonprescription Drug Products Guidance for Industry,Other,Guidance,2022-11-25T05:00:00Z,2022,11,2022-11-25T05:00:00Z,,2024-11-12T23:47:18Z,,1,0,0900006485500486
FDA-2022-N-1794-0001,FDA,FDA-2022-N-1794,Agency Information Collection Activities; Proposed Collection; Comment Request; General Drug Labeling Provisions and Over-the-Counter Monograph Drug User Fee Submissions,Notice,60 Day Proposed Information Collection,2022-09-09T04:00:00Z,2022,9,2022-09-09T04:00:00Z,2022-11-09T04:59:59Z,2022-09-09T12:52:16Z,2022-19502,0,0,09000064852d6bd2